Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

  • End date
    Oct 1, 2024
  • participants needed
  • sponsor
    NanoPharmaceuticals LLC
Updated on 4 October 2022
karnofsky performance status
brain tumor
recurrent glioblastoma


Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.

Condition Glioma, Malignant
Treatment fb-PMT
Clinical Study IdentifierNCT05226494
SponsorNanoPharmaceuticals LLC
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Histologically proven intracranial glioblastoma, with first or second recurrence
On stable or decreasing dose of steroids, if taken prior to screening
Baseline MRI (with and without contrast) completed with 5 days of starting fb-PMT
Prior completion of and recovery from the effects of standard of care for glioblastoma management with surgery/biopsy and radiotherapy
Confirmation of true progressive disease for patients previously treated with interstitial brachytherapy or stereotactic radio surgery
Life expectancy of more than three months
Karnofsky Performance Status of ≥ 70
Hypertension must be well controlled (≤ 95th percentile) on stable doses of medication
Adequate bone marrow and organ function, confirmed by laboratory testing at screening
Patient or caregiver must be able to store drug under refrigerated conditions, prepare and administer daily subcutaneous injections on a set schedule, and record information in a daily treatment diary
Women of childbearing potential must agree to ongoing pregnancy testing and to use medically acceptable contraception for the duration of the study and for 2 months after their last dose of study drug
Males must agree to use medically acceptable contraception and refrain from donating sperm for the duration of the study and for 2 months after their last dose of study drug

Exclusion Criteria

Significant medical illness that is uncontrolled, may obscure toxicity, may dangerously alter drug metabolism, or may compromise ability for study participation
History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for at least 3 months prior to first dose of study drug
Use of bevacizumab or any other experimental drug or therapy within 28 days of study treatment
Prior therapy with fb-PMT or related drugs
Currently pregnant or breastfeeding
Active infection or serious intercurrent medical illness
Surgery of any type within the preceding 28 days that has not fully healed
A serious or non-healing wound, ulcer, or bone fracture
A known bleeding diathesis or coagulopathy, or a history of bleeding diathesis within 28 days of study treatment
A known thrombophilic condition (i.e., protein S, protein C, or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia or antiphospholipid antibody syndrome). Testing is not required in patients without thrombophilic history
Evidence of new central nervous system hemorrhage on baseline MRI obtained within 14 days prior to study enrollment
Clinically significant cardiovascular event such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening
New York Heart Association classification of heart disease greater than Class 2
QTc interval > 450 msec in males or > 470 msec in females at screening
Use of concomitant medications that prolong the QT/QTc interval or risk inducing Torsades de Pointes
Use of any concomitant Cytochrome P450 (CYP) inhibitors or CYP inducers within 14 days or five half-lives (whichever is longer) before starting study drug treatment
Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to study enrollment
A significant vascular disease (e.g., aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study enrollment
History of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past 6 months
History of Torsades de Pointes or risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note